Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantern Pharma Inc.LTRN · Entity 7525 | Chief Financial Officer | December 18, 2025 | December 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantern Pharma Inc.
Report date December 18, 2025 · Filed December 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2035-12-17 | Direct | 20,000 |
Reported balance
After 2025-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-18 · Grant · Acquired 20,000 · Balance 20,000 F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 22, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001493152-25-028759 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-12-17 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028186 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001213900-21-056108 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock · 26,100 shares Expires 2031-10-29 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon November 29, 2021. Read SEC document |
| October 29, 2021 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001493152-25-014612 · ownership.xml · derivative · entry 4 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock · 26,100 shares Expires 2031-10-28 F2 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021. F2 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021. Read SEC document |
| October 29, 2021 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001493152-25-014612 · ownership.xml · derivative · entry 3 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,100 shares Expires 2031-10-28 F2 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021. F2 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 17:32 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option · Derivative | 78,300 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001213900-20-015047 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,300 Underlying: Common Stock · 78,300 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Financial Officer, the Reporting Person was granted stock options to purchase 78,300 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the "Grant Date"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · price: Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Financial Officer, the Reporting Person was granted stock options to purchase 78,300 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the "Grant Date"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · derivative.exercise_date: Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Financial Officer, the Reporting Person was granted stock options to purchase 78,300 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the "Grant Date"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · derivative.expiration_date: Pursuant to the employment agreement between the Issuer and the Reporting Person as Chief Financial Officer, the Reporting Person was granted stock options to purchase 78,300 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") under the terms and conditions of the Issuer's Amended and Restated 2018 Equity Incentive Plan. The exercise price equals the price per share sold in the Issuer's offering. One-third of the options will vest 180 days from the closing of the Issuer's IPO (the "Grant Date"), with the remaining two-thirds of the options vesting in equal monthly increments over the period commencing the 181st day after the Grant Date and ending 30 months thereafter (or 36 months after the Grant Date). Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. Read SEC document |
| June 15, 2020 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 78,300 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001493152-25-014612 · ownership.xml · derivative · entry 2 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,300 Underlying: Common Stock · 78,300 shares Expires 2030-06-14 F1 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). Read SEC document |
| June 15, 2020 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,300 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001493152-25-014612 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,300 shares Expires 2030-06-14 F1 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.